Tuesday, October 25th, 2016

 

Breaking News: FDA MedWatch – Testosterone and Other Anabolic Androgenic Steroids (AAS): FDA Statement – Risks Associated With Abuse and Dependence

Today the FDA has issued a statement giving approval for “class-wide labeling changes for all prescription testosterone products, adding a new Warning and updating the Abuse and Dependence section to include new safety information from published literature and case reports regarding the risks associated with abuse and dependence of testosterone and other AAS.” FDA Safety Alert